AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31196083
Drug: Beliefs about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beliefs about Medicines Questionnaire (BMQ)
Trial: 31196083
Drug: Satisfaction with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satisfaction with Information about Medicines Scale (SIMS)
Trial: 31198489
Drug: Hormonal skin
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal skin diagnostic testing with intradermal injections of Progesterone, Estradiol, Estrone, and Estriol; followed by serial desensitization injections
Trial: 31198489
Drug: Placebo solvent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solvent injections
Trial: 31199335
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (NRT) provided for up to 3 months upon request, along with continuous smoking cessation (SC) counseling and behavioral support.
Trial: 31199335
Drug: Safety assessments
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety assessments included adverse events and serious adverse events, body weight, vital signs, spirometry, electrocardiogram, clinical chemistry, hematology and urine analysis safety panel, physical examination, and concomitant medications.
Trial: 31199341
Drug: Adjunct treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct treatment components tailored for YMSM including assertive communication training videos and motivational interviewing focused on assisting with identification and development (MI-AID) before CHTC.
Trial: 31199347
Drug: Arousal feedback-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arousal feedback-based exposure therapy
Trial: 31201085
Drug: De-escalation of
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation of TKI treatment to half the standard dose for 12 months, then stopped for a further 24 months.
Trial: 31201169
Drug: Daratumumab (DARA)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab (DARA) 16 mg/kg
Trial: 31201169
Drug: Subcutaneous bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous bortezomib (1.3-1.5 mg/m2)
Trial: 31204145
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (60-min session, three times a week for three months)
Trial: 31204595
Drug: IN.PACT Admiral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN.PACT Admiral Drug-Coated Balloon
Trial: 31205473
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose antivenom
Trial: 31205473
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose antivenom
Trial: 31205473
Drug: Preantivenom subcutaneous
RxNorm normalized name: Viper antivenom
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preantivenom subcutaneous adrenaline (SCAd)
Trial: 31205473
Drug: IV adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV adrenaline infusion (IVAI)
Trial: 31206074
Drug: 2-year camp-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-year camp-based immersion family treatment for obesity
Trial: 31206074
Drug: outpatient family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: outpatient family-based treatment for obesity
Trial: 31207561
Drug: Controlled pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled pharmacotherapy for psychotic depression
Trial: 31208944
Drug: Ibrutinib plus
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib plus FCR (Fludarabine, Cyclophosphamide, Rituximab); Ibrutinib 420 mg/day for 7 days, followed by up to six 28-day cycles of FCR.
Trial: 31211792
Drug: Killed bivalent
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed bivalent (Vibrio cholerae O1 and O139) whole-cell oral cholera vaccine (SHANCHOL; Shantha Biotechnics) - 2 doses, 14 days apart
Trial: 31212080
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) administered post-transplant
Trial: 31212683
Drug: Educational text
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational text messages (3 messages weekly for 12 weeks)
Trial: 31212833
Drug: P28GST administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P28GST administration
Trial: 31212833
Drug: P28GST treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P28GST treatment in Crohn's disease patients
Trial: 31213500
Drug: Binimetinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib (30 mg b.i.d.) and Pexidartinib (400 mg every morning and 200 mg every evening)
Trial: 31213778
Drug: Nurse-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-based intervention for improving medication adherence
Trial: 31214997
Drug: Trelagliptin 100
RxNorm normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Trelagliptin 100 mg once weekly for 12 weeks
Trial: 31214997
Drug: Daily DPP-4
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily DPP-4 inhibitor for 12 weeks
Trial: 31214997
Drug: Daily DPP-4
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily DPP-4 inhibitor
Trial: 31214997
Drug: Trelagliptin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trelagliptin and daily DPP-4 inhibitors
Trial: 31215195
Drug: Fluorescent imaging
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescent imaging agent IS-001
Trial: 31215264
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin and fondaparinux (Control)
Trial: 31216011
Drug: Incretin-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incretin-based therapies
Trial: 31216011
Drug: Exogenous incretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exogenous incretin infusions
Trial: 31217479
Drug: TSR-011 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSR-011 40 mg every 8 hours (Q8h)
Trial: 31217479
Drug: TSR-011 320-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSR-011 320- and 480-mg Q24h doses
Trial: 31217479
Drug: TSR-011 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSR-011 40 mg Q8h
Trial: 31217818
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan at 80 mg/m² in combination with capecitabine-based radiotherapy (50 Gy/25 fractions)
Trial: 31217992
Drug: Home-based heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based heart failure tool (education, symptom monitoring, diuretic titration)
Trial: 31217993
Drug: HART PAD
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HART PAD panel (clinical variable: history of hypertension; biomarkers: midkine, kidney injury molecule-1, interleukin-23, follicle-stimulating hormone, angiopoietin-1, eotaxin-1)
Trial: 31218013
Drug: Accelerated initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Accelerated initiation of renal replacement therapy (RRT) within 12 hours of meeting eligibility criteria
Trial: 31218013
Drug: Standard initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initiation of renal replacement therapy (RRT) based on clinician judgment or urgent complications
Trial: 31219975
Drug: Intensive combined
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive combined chemotherapy (C-CAR-cohort)
Trial: 31220258
Drug: Cefoxitin (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (loading dose followed by constant infusion)
Trial: 31220258
Drug: Cefoxitin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (standard dosing regimen)
Trial: 31220276
Drug: Subcutaneous (sc)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (sc) prolonged suppressive antibiotic therapy (PSAT) using ertapenem, ceftriaxone, or ceftazidime
Trial: 31220276
Drug: Subcutaneous (sc)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (sc) PSAT
Trial: 31220349
Drug: Ledipasvir-sofosbuvir (weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir-sofosbuvir (weight-based doses: 33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks
Trial: 31220400
Drug: Salvage radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiotherapy (SRT) with pre-SRT PSA level <0.5 ng/mL
Trial: 31220400
Drug: Delayed SRT
RxNorm normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed SRT with PSA level ≥0.5 ng/mL
Trial: 31220400
Drug: Early SRT
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early SRT at PSA level <0.5 ng/mL
Trial: 31220400
Drug: SRT alone
RxNorm normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT alone in patients with PSA level ≥0.5 ng/mL and higher-risk features
Trial: 31220623
Drug: Rapid saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid saline infusion
Trial: 31220942
Drug: S100a9 neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S100a9 neutralizing antibody administration
Trial: 31222720
Drug: G-estimation using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-estimation using a quadratic approximation approach inspired by iteratively reweighted least squares.
Trial: 31222722
Drug: CUSP9-LD (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUSP9-LD (low-dose CUSP9) combined with Bcl-2/Bcl-xL inhibitor ABT263
Trial: 31222783
Drug: Sofosbuvir plus
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir plus ribavirin for 12 weeks (genotype 2) or 24 weeks (genotype 3); Sofosbuvir dosage: 150 mg for patients aged 3 to <6 years weighing <17 kg, 200 mg for patients aged 3 to <6 years weighing ≥17 kg and all patients aged 6 to <12 years; Ribavirin dosing based on weight (up to 1,400 mg/day, two divided doses).
Trial: 31225870
Drug: Human subcutaneous
RxNorm normalized name: IgG, human subcutaneous 16 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human subcutaneous adipose tissue ATG7 mRNA expression
Trial: 31225872
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) treatment of MCF7 cells
Trial: 31225872
Drug: GR antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GR antagonist RU486
Trial: 31226985
Drug: Other approved
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other approved therapies
Trial: 31227534
Drug: Highly-interventional spasticity
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Highly-interventional spasticity management (including SDR, ITB, anti-spasticity injections and medications)
Trial: 31228101
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg no-load
Trial: 31228101
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg or 150 mg no-load
Trial: 31228101
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg (after dose escalation)
Trial: 31228177
Drug: SMART4MD app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SMART4MD app on a data-enabled computer tablet, used daily at home.
Trial: 31228214
Drug: Alcoholic hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic hepatitis patients with ASCA levels ≥34 IU/mL
Trial: 31228626
Drug: Durvalumab 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 10 mg/kg every 2 weeks for 12 months
Trial: 31228628
Drug: Ig20Gly infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ig20Gly infusion at rates of ≥60 mL/h/site
Trial: 31228628
Drug: Ig20Gly infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ig20Gly infusion
Trial: 31228943
Drug: Fluid resuscitation
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid resuscitation with 250 ml albumin 5% boluses repeated as required to restore PPV to < 15% (Fluid non-Responding Status - FnRS)
Trial: 31231122
Drug: RRx-001 4
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 4 mg IV on day 1 of each week of a 21-day cycle followed by platinum plus etoposide (80-100 mg IV) at progression
Trial: 31231785
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg daily for 12 weeks
Trial: 31233323
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) intervention, details on dosage and duration not available.
Trial: 31235441
Drug: Ribociclib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (400 mg per day continuously) plus trastuzumab (6 mg/kg every 3 weeks)
Trial: 31235483
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy plus biweekly cetuximab as first-line therapy
Trial: 31235630
Drug: High-dose ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ceftriaxone (75 to 100 mg/kg of body weight/day)
Trial: 31235775
Drug: Bevacizumab (BVZ)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BVZ) added to chemotherapy plus trastuzumab (Trast)
Trial: 31235775
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab (Trast)
Trial: 31235963
Drug: T cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell receptor gene therapy targeting WT1
Trial: 31236579
Drug: Toripalimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (3 mg/kg d1, Q2W) as monotherapy in cohort 1
Trial: 31236579
Drug: Toripalimab (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (360 mg d1, Q3W) with oxaliplatin (130 mg/m2 qd, d1) and capecitabine (1000 mg/m2 b.i.d., d1-d14, Q3W) in cohort 2
Trial: 31236847
Drug: Neoadjuvant nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nivolumab therapy
Trial: 31237206
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy for Leber's hereditary optic neuropathy
Trial: 31237839
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of internal facilitator coaching with encouragement of communities of practice (CoPs)
Trial: 31238830
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) with or without intravenous tPA (IVT)
Trial: 31238830
Drug: Intravenous tPA
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tPA (IVT) only
Trial: 31239857
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LAT and MAT
Trial: 31240302
Drug: Zolbetuximab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab (monoclonal antibody) administered intravenously every 2 weeks for five planned infusions; cohorts received doses of 1300 mg/m2, 2600 mg/m2, and 3600 mg/m2.
Trial: 31240499
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) monotherapy or combination therapy
Trial: 31244718
Drug: Fertility treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fertility treatment (supraphysiological estradiol levels)
Trial: 31244760
Drug: CX-8998, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX-8998, a selective modulator of the T-Type calcium channel
Trial: 31245054
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept 125 mg weekly for 24 weeks
Trial: 31245160
Drug: Intraoperative endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative endoscopic submucosal injection of dual tracer (radioisotope and indocyanine green) with sentinel basins detected using gamma-probe
Trial: 31245160
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection of indocyanine green (ICG) with sentinel basins detected using a fluorescence imaging system
Trial: 31247117
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg adefovir-dipivoxil (OAT1)
Trial: 31250322
Drug: Brivaracetam oral
RxNorm normalized name: brivaracetam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam oral solution (dosage increased weekly: 0.8, 1.6, 3.2 mg/kg/day for patients ≥ 8 years; 1.0, 2.0, 4.0 mg/kg/day for patients < 8 years)
Trial: 31250322
Drug: Brivaracetam oral
RxNorm normalized name: brivaracetam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam oral solution
Trial: 31250445
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or vortioxetine) for 8 weeks
Trial: 31250829
Drug: Feminizing hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feminizing hormone therapy and adherence counseling; Peer health navigation
Trial: 31251543
Drug: 0.3% A/BPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% A/BPO treatment
Trial: 31253572
Drug: IPH4102 (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPH4102 (monoclonal antibody targeting KIR3DL2) administered as an intravenous infusion at a flat dose of 750 mg during cohort-expansion.
Trial: 31253596
Drug: AMG 232
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 232 monotherapy (arm 1) at doses of 60, 120, 240, 360, 480, or 960 mg
Trial: 31253596
Drug: AMG 232
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 232 at 60 mg with trametinib 2 mg (arm 2)
Trial: 31253596
Drug: Common treatment-related
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common treatment-related AEs for AMG 232
Trial: 31253596
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of AMG 232
Trial: 31253727
Drug: Peg-IFN-α2a monotherapy
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFN-α2a monotherapy after 12 weeks
Trial: 31253727
Drug: Peg-IFN-α2a immunotherapy
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFN-α2a immunotherapy
Trial: 31253732
Drug: Self-reported questionnaires
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported questionnaires including the Hospital Anxiety and Depression Scale, the Functional Assessment of Cancer Therapy (FACT), General and Brain (FACT-Br), and the Leisure Time Physical Activity Questionnaire.